Venus Remedies Ltd
Venus Remedies Ltd Share Price Today: Live Updates & Key Insights
Get insights on Venus Remedies Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Venus Remedies Ltd Share Price Chart
Venus Remedies Ltd Fundamentals
Traded Volume: 22,320
Market Cap(Cr): 597
Avg Traded Price 227.35
1 Year return 38.90%
Upper Circuit 448.3
Lower Circuit 436.6
P/E TTM 11.00
P/B Ratio 40.00
Traded Value(Cr) 99.61
EPS TTM 40.185
Book value 40.185
Dividend 0.00%
Venus Remedies Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Venus Remedies Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Venus Remedies Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W +1.56%
1M -5.11%
3M -10.54%
1Y +38.90%
YTD +38.76%
Venus Remedies Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Venus Remedies Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 12792.00
Day Before Yesterday 15627.00
1W Avg 13145.75
1M Avg 28399.95
3M Avg 22445.93
Venus Remedies Ltd Technical Details
Venus Remedies Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 439
Support 2 432
Support 3 428
Pivot Point : 444
Resistance 1 451
Resistance 2 455
Resistance 3 463
Venus Remedies Ltd Corporate Actions
Venus Remedies Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Venus Remedies Ltd’s capital allocation strategies.
All
Ex-Date 23-Sep-2013 Type D Description 3.00/share@30.00% Record Date 07-Nov-2025 Ratio 30.00
Ex-Date 20-Sep-2012 Type D Description 3.00/share@30.00% Record Date 07-Nov-2025 Ratio 30.00
Ex-Date 22-Sep-2011 Type D Description 3.00/share@30.00% Record Date 07-Nov-2025 Ratio 30.00
Ex-Date 23-Sep-2010 Type D Description 3.00/share@30.00% Record Date 07-Nov-2025 Ratio 30.00
Ex-Date 17-Sep-2009 Type D Description 3.00/share@30.00% Record Date 07-Nov-2025 Ratio 30.00
Ex-Date 12-Sep-2008 Type D Description 4.00/share@40.00% Record Date 07-Nov-2025 Ratio 40.00
Ex-Date 18-Sep-2007 Type D Description 3.00/share@30.00% Record Date 07-Nov-2025 Ratio 30.00
Dividends
Announcement Date 23-Sep-2013 Ex Dividend Date 23-Sep-2013 Dividend(%) 30
Announcement Date 20-Sep-2012 Ex Dividend Date 20-Sep-2012 Dividend(%) 30
Announcement Date 22-Sep-2011 Ex Dividend Date 22-Sep-2011 Dividend(%) 30
Announcement Date 23-Sep-2010 Ex Dividend Date 23-Sep-2010 Dividend(%) 30
Announcement Date 17-Sep-2009 Ex Dividend Date 17-Sep-2009 Dividend(%) 30
Announcement Date 12-Sep-2008 Ex Dividend Date 12-Sep-2008 Dividend(%) 40
Announcement Date 18-Sep-2007 Ex Dividend Date 18-Sep-2007 Dividend(%) 30
Bonus
No Bonus has been declared by VENUSREM
Splits
No Split has been declared by VENUSREM
Others
Rights No Rights has been declared by VENUSREM
Venus Remedies Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Venus Remedies Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Venus Remedies Ltd's relative performance and valuation against major competitors.
Stock Name Accent Microcell Ltd ₹281.30 (+0.21%) M. Cap (Cr) 6.75 1 Yr Return (%) +15.24% P/E (TTM) 20.41 PB Ratio 2.88
Stock Name Kilitch Drugs (India) Ltd ₹379.50 (+0.66%) M. Cap (Cr) 6.63 1 Yr Return (%) +23.27% P/E (TTM) 23.69 PB Ratio 2.63
Stock Name Shree Ganesh Remedies Ltd ₹489.10 (-0.63%) M. Cap (Cr) 6.28 1 Yr Return (%) -38.56% P/E (TTM) 30.76 PB Ratio 4.72
Stock Name Venus Remedies Ltd ₹446.30 (+1.03%) M. Cap (Cr) 5.97 1 Yr Return (%) +38.90% P/E (TTM) 11.11 PB Ratio 1.06
Stock Name Vikram Thermo (India) Ltd ₹176.80 (+0.74%) M. Cap (Cr) 5.54 1 Yr Return (%) +1.61% P/E (TTM) 17.39 PB Ratio 5.27
Stock Name Medicamen Biotech Ltd ₹405.75 (+1.58%) M. Cap (Cr) 5.50 1 Yr Return (%) -22.76% P/E (TTM) 61.51 PB Ratio 2.54
Stock Name Jenburkt Pharmaceuticals Ltd ₹1202.80 (-1.15%) M. Cap (Cr) 5.31 1 Yr Return (%) -2.37% P/E (TTM) 15.92 PB Ratio 3.06
Venus Remedies Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Venus Remedies Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2025 83.10 Mar 2024 35.38 Mar 2023 28.05 Mar 2022 40.90 Mar 2021 132.67
PARTICULARS Investing Activities Mar 2025 -76.20 Mar 2024 -6.94 Mar 2023 -50.81 Mar 2022 -16.65 Mar 2021 55.65
PARTICULARS Financing Activities Mar 2025 0.00 Mar 2024 0.00 Mar 2023 0.00 Mar 2022 -9.13 Mar 2021 -161.88
PARTICULARS Net Cash Flow Mar 2025 6.90 Mar 2024 28.44 Mar 2023 -22.76 Mar 2022 15.12 Mar 2021 26.44
Venus Remedies Ltd Shareholding Pattern
This shows the ownership breakdown of Venus Remedies Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 41.76%
Public 55.62%
Other Institutions 0.75%
FII 1.86%
Mutual Funds null%
About Venus Remedies Ltd
Incorporated in 1989 Venus Remedies Ltd (formerly known Venus Glucose Pvt Ltd), was converted into Public Limited Company in 1994 and then changed into Venus Remedies Limited. The Company was promoted and managed by Chaudhary & Family. The Company is one of the handful player in pharmaceutical sector to launch injectables globally. It has manufacturing facilities in Panchkula and Baddi , and research and development centre under the name of Venus Medicine Research Centre (in India). In priority, the Company was mainly engaged in I/V Fluids & Injectables, Ceftazidime, Amlodipine, Gliclazide, Lisinopril, etc. The production was started in 1991 with Intravenous/Intramuscular injectible forms at Panchkula district at Haryana. In 1994 it introduced Eye/Ear/Nose drops. The company received the certificate as `WHO-GMP` as specified by WHO,Geneva. Venus Remedies set up a Cephalosporin project with an Australian collaboration with US-FDA standards at a cost of Rs.4.5 crores. The company is manufacturing injections for the top companies like Panacea Biotech ltd,Morepan Labortories ltd etc. In 2001 with the help of Product Development Committee(PDC) Venus Remedies had introduced 13 new products in the Animal Health Division namely Megox-3000,Paroxin-3000,Pisa-3000,Mical,Ronid,Dexolyte and Detox. The year 2005-06 saw many new milestone achievements by the Company like commercial operation of its most modern and techno-savvy manufacturing unit at Baddi, formation of a WOS in Germany and acquisition of a running, German-GMP certified pharmaceutical unit at Werne, Germany, launch of its second R&D Product after DCGI Approval etc. There was a rigorous activity for development on all fronts and the Company made huge investments in projects at Panchkula, Baddi and now at Werne, Germany for renovations, new Projects and acquisition as well. The Company was the first to launch Injection Meropenem in Paediatric Dosage of 125 mg in its Domestic Marketing during the year 2006-07. It further launched fourth research product, a fixed dose combination of cephalosporin with aminoglycoside under the `Tobracef` brand in 2008-09. It launched its anti-cancer drug `Docetaxel` in Europe by end 2011, launched ACHNIL, the once-a-day pain management therapy in India in 2011; launched `Cytomib`, a first-time therapy against blood cancer in 2011; launched `Taxedol` in three strengths-20 mg, 80 mg and 120 mg in 2012. In 2013, the Company established pre-clinical proof of concept for its Drug -Protein-Polymer- Conjugate (DPPC); introduced Ready-to-Use a Single Vial Taxedol in India; launched `Trois`, a miracle nano-emulsion for arthritic Pain; launched `Elores` - CSE 1034, a US patent protected product in India, launched its first OTC product "Ezenus". In 2014, the Company launched ELORES, an antibiotic to fight `superbugs`. In 2021-22, it launched first product in the consumer healthcare space, R3SET - a Pain Management solution. Besides this, Venpocare dealing with Wound Healing was also launched during year 2022. To make internal processes smart and streamlined, many solutions including an automated order processing system, retail billing system, new warehouse (VFC) with barcode automation, etc. were launched. For quicker and more effective decision-making, a BI tool like Tableau was also launched in 2022.
Chairman & Managing Director
Pawan Chaudhary
Registered office S C No 857 Cabin No 10 2nd Flr, N A C Manimajra, Chandigarh, Chandigarh, 160101
FAX :null
Background
Incorporation Year 1989
Face Value ₹10.00
Market Lot 1
FAQs on Venus Remedies Ltd
How to buy Venus Remedies Ltd shares on NSE?
To buy Venus Remedies Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the Venus Remedies Ltd share price today?
The Venus Remedies Ltd share price on NSE is ₹446.30 today.
What is the market cap of Venus Remedies Ltd on NSE?
The company has a market capitalization of ₹596.57.
What is the PE & PB ratio of Venus Remedies Ltd?
PE is 11 and PB is 40.
What is the 52 Week High and Low of Venus Remedies Ltd shares?
Venus Remedies Ltd stock price high: ₹567.80 Venus Remedies Ltd stock price low: ₹270.25.